Shopping Cart
- Remove All
- Your shopping cart is currently empty
Nusinersen (nusinersen) is an antisense oligonucleotide (ASO) for the treatment of pediatric and adult spinal muscular atrophy (SMA) that alters the way the SMN2 gene is processed and increases the production of SMN proteins, which are deficient in SMA patients.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $347 | In Stock | |
5 mg | $987 | In Stock | |
10 mg | $1,560 | In Stock | |
25 mg | $2,320 | In Stock | |
50 mg | $3,130 | In Stock |
Description | Nusinersen (nusinersen) is an antisense oligonucleotide (ASO) for the treatment of pediatric and adult spinal muscular atrophy (SMA) that alters the way the SMN2 gene is processed and increases the production of SMN proteins, which are deficient in SMA patients. |
In vivo | In the ENDEAR phase 3 clinical trial, intrathecal administration of Nusinersen in infants with spinal muscular atrophy significantly improved outcomes. A motor milestone response was observed in 51% of treated infants (vs. 0% in controls), with increased event-free survival (HR = 0.53) and overall survival (HR = 0.37)[1].In severe SMA mouse models, a single subcutaneous injection of Nusinersen (30 μg) on postnatal day 1 significantly extended survival, improved motor neuron function, neuromuscular junction integrity, and motor behavior[2]. |
Cas No. | 1258984-36-9 |
Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.